GIM
PFE icon

Glenmede Investment Management’s Pfizer PFE Stock Holding History

Glenmede Investment Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$24.4M Sell
958,252
-127,376
-12% -$3.14M 0.12% 156
2025
Q2 		$26.3M Buy
+1,085,628
New +$25.3M 0.13% 142

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Glenmede Investment Management's PFE Position: Q3 2025 in Review

Glenmede Investment Management reduced its Pfizer (PFE) stake by 12% in Q3 2025, selling an estimated $3.14M and leaving 958,252 shares worth $24.4M. The position accounts for 0.12% of the portfolio, ranked #156.

Glenmede Investment Management first reported a position in PFE in Q2 2025 and has held it in 2 quarters since. The position peaked at $26.3M in Q2 2025. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • Glenmede Investment Management held 958,252 shares of Pfizer worth $24.4M as of Q3 2025.
  • Glenmede Investment Management sold 127,376 Pfizer shares in Q3 2025, an estimated $3.14M.
  • Pfizer made up 0.12% of Glenmede Investment Management's portfolio in Q3 2025, its #156 holding.
  • Glenmede Investment Management first reported a position in Pfizer in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Pfizer position peaked at $26.3M in Q2 2025.
  • 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.